NDATOPICALCREAM
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANDEL is a topical hydrocortisone probutate cream indicated for inflammatory and pruritic dermatological conditions. It is a moderate-potency corticosteroid applied directly to affected skin areas. The drug works by suppressing local inflammatory responses and reducing pruritus through corticosteroid receptor activation.
$0.04MPart D
LOE ApproachingWith LOE approaching and minimal recent claims activity, this product is in maturity/decline phase with limited commercial growth opportunities and likely a lean, stable team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PANDEL offers limited career upside given its LOE-approaching status and minimal market activity ($40K Part D spending, 33 claims in 2023). This is a stable but declining product best suited for professionals seeking maintenance-mode brand experience or cost management expertise rather than growth-oriented opportunities.
Brand ManagerField Sales Representative
Worked on PANDEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.